Clinical Trial Update: A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating TAK-931 in participants with advanced nonhematologic neoplasms has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Nonhematologic Neoplasms

Drugs mentioned

• TAK-931 (TAK-931)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Nonhematologic Neoplasms, Advanced | Phase 1 | Status: COMPLETED | Results posted: 2021-02-21